THE DYNAMIC U.S. RESEARCH AND DEVELOPMENT ECOSYSTEM

The rapid pace of scientific advances and our growing understanding of the underlying mechanisms of disease are fueling the development of new treatments and cures for patients. At the same time, the cost, time and complexities of biopharmaceutical research have increased, introducing additional challenges in the research and development (R&D) and manufacturing processes. As scientific complexities create new challenges, research-based biopharmaceutical companies are committed to realizing the promise of the pipeline and are working with stakeholders across the dynamic U.S. R&D ecosystem to leverage new scientific and technological advances to bring innovative medicines to patients. With about 7,000 medicines in clinical development globally – of which 74 percent have the potential to be first-in-class treatments – the future has never been brighter.1, ii

AMERICA’S BIOPHARMACEUTICAL COMPANIES PLAY CENTRAL ROLE IN R&D ECOSYSTEM

U.S. biopharmaceutical companies play a central role in the biomedical research ecosystem. The complex system is marked by collaborations across industry, academic institutions, government agencies, venture capital firms, nonprofit foundations and others. This diverse group of stakeholders works together to advance science from the bench to the bedside. Early scientific advances form the foundation for the development of new medicines, which is led by biopharmaceutical companies.

THE COMPLEX BIOPHARMACEUTICAL R&D PROCESS

The drug development process typically begins with the screening of an enormous number of potential medicines. On average it takes 10 to 15 years for a medicine to make its way from the start of the R&D process to approval by the U.S. Food and Drug Administration (FDA) (See Figure 2 and Sidebar: Biopharmaceutical Research and Development Process). And only 12 percent of investigational medicines entering clinical trials are ultimately approved by the FDA.iii

The average cost to develop a new medicine is estimated at $2.6 billion dollars, including the cost of those that fail. The cost of development has more than doubled over the past decade.iv Over this same period, rapid scientific and technical advances, alongside increasing regulatory burdens, are resulting in more complex clinical trials. For example, one study found that between 2001 and 2015, the total number of endpoints within a typical Phase III trial grew 86 percent and the number of procedures (including routine exams, blood work and x-rays) grew by 70 percent.v Despite these challenges, biopharmaceutical research companies remain committed to bringing important new treatment options to patients. PhRMA member companies themselves have invested more than half a trillion dollars in R&D since 2000.vi
THE EVOLVING R&D PROCESS

Researchers are constantly seeking to refine the R&D process in response to new scientific and technological advances and evolving regulatory requirements.

The 21st Century Cures Act and the Prescription Drug User Fee Act (PDUFA) help ensure that the FDA has the tools and resources needed to better manage the significant emerging science and innovation of today to meet the challenges of tomorrow. Increasing acceptance of innovative clinical trial designs, appropriate integration of the patient perspective and advancing the use of real-world evidence all hold potential in speeding the development and regulatory review process and in enhancing the competitive marketplace through the introduction of innovative new medicines.

While new scientific advances bring greater promise and complexity, the process is inherently fraught with a high degree of scientific and regulatory uncertainty, and there are often research setbacks. For example, between 1998 and 2014, 128 potential medicines for the treatment of Alzheimer’s disease did not make it through clinical trials, with only four gaining FDA approval. Despite these challenges, researchers remain committed to conquering challenging diseases such as Alzheimer’s. Today, there are 92 Alzheimer medicines in clinical development or awaiting FDA review.

PROVIDING HOPE TO PATIENTS

By all accounts, we are in an unprecedented period of medical discovery, driving new cures and treatments for many of our most costly and debilitating diseases and providing options that allow many to live longer, healthier lives. However, in many ways, our work is just getting started.

It is critical that we have a policy and regulatory environment that promotes innovation to fulfill the promise that these scientific opportunities represent for patients. To continue to advance medical discovery, we need to ensure a well-functioning, science-based regulatory system that keeps pace with the latest advances and ensures the timely review, approval and introduction of new medicines. This will be critical not only in improving the lives of patients, but also in maintaining U.S. global leadership in biomedical innovation and sustaining and growing U.S. jobs. Finally, it is important that we have robust intellectual property (IP) rights and incentives to foster investment in R&D and commercialization of new technologies, including enforcement of IP protections in the United States and abroad.

vii PhRMA annual membership survey. Washington, DC: PhRMA.